DK0758248T3 - Formuleringer til faktor IX - Google Patents

Formuleringer til faktor IX

Info

Publication number
DK0758248T3
DK0758248T3 DK95915040T DK95915040T DK0758248T3 DK 0758248 T3 DK0758248 T3 DK 0758248T3 DK 95915040 T DK95915040 T DK 95915040T DK 95915040 T DK95915040 T DK 95915040T DK 0758248 T3 DK0758248 T3 DK 0758248T3
Authority
DK
Denmark
Prior art keywords
factor
formulations
administration
methods
storage
Prior art date
Application number
DK95915040T
Other languages
English (en)
Inventor
Lawrence Bush
Chandra Webb
Original Assignee
Inst Genetics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Genetics Llc filed Critical Inst Genetics Llc
Application granted granted Critical
Publication of DK0758248T3 publication Critical patent/DK0758248T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK95915040T 1994-04-26 1995-04-06 Formuleringer til faktor IX DK0758248T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/233,663 US6372716B1 (en) 1994-04-26 1994-04-26 Formulations for factor IX
PCT/US1995/004263 WO1995028954A1 (en) 1994-04-26 1995-04-06 Formulations for factor ix

Publications (1)

Publication Number Publication Date
DK0758248T3 true DK0758248T3 (da) 2003-10-27

Family

ID=22878181

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95915040T DK0758248T3 (da) 1994-04-26 1995-04-06 Formuleringer til faktor IX

Country Status (11)

Country Link
US (1) US6372716B1 (da)
EP (1) EP0758248B1 (da)
JP (4) JPH09512267A (da)
AT (1) ATE244015T1 (da)
AU (1) AU695084B2 (da)
CA (1) CA2182200C (da)
DE (1) DE69531204T2 (da)
DK (1) DK0758248T3 (da)
ES (1) ES2202356T3 (da)
PT (1) PT758248E (da)
WO (1) WO1995028954A1 (da)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US7786070B2 (en) 1997-09-10 2010-08-31 Novo Nordisk Healthcare A/G Subcutaneous administration of coagulation factor VII
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP5090605B2 (ja) 2000-05-03 2012-12-05 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 凝固因子ｖｉｉの皮下投与
WO2002039951A2 (en) * 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
CN1607958A (zh) 2001-12-21 2005-04-20 诺和诺德医疗保健公司 因子ⅶ多肽的液体组合物
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
ES2523655T5 (es) 2002-06-21 2018-04-23 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
CA2513722A1 (en) * 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
BRPI0409936A (pt) 2003-05-23 2006-04-25 Novo Nordisk Healthcare Ag uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
PE20050627A1 (es) * 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
ES2382157T3 (es) 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
KR101293503B1 (ko) 2003-08-14 2013-08-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
TR201809670T4 (tr) 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Faktör VII polipeptitlerinin stabilize edilmiş kompozisyonları.
KR101146160B1 (ko) 2004-06-30 2012-07-16 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US7625560B2 (en) * 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
ES2434732T3 (es) * 2004-12-15 2013-12-17 Janssen Alzheimer Immunotherapy Anticuerpos para beta-amiloide humanizados para su uso en mejorar la cognición
CA2589017A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
BRPI0606867A2 (pt) * 2005-01-28 2009-07-21 Wyeth Corp formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
KR101502920B1 (ko) 2005-06-21 2015-03-17 조마 (유에스) 엘엘씨 ＩＬ-１β 결합성 항체 및 그의 단편
DK3225233T3 (da) 2005-11-01 2019-10-14 Wyeth Llc Natriumchloridopløsning til rekonstituering af lægemiddel
EP1951305A1 (en) * 2005-11-22 2008-08-06 Wyeth a Corporation of the State of Delaware Immunoglobulin fusion protein formulations
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US20080292625A1 (en) * 2007-04-18 2008-11-27 Sally Schroeter Prevention and treatment of cerebral amyloid angiopathy
MX2009012964A (es) * 2007-06-01 2010-01-14 Acologix Inc Formulacion de peptido estable a alta temperatura.
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
ES2527326T3 (es) 2007-12-20 2015-01-22 Xoma (Us) Llc Métodos para el tratamiento de la gota
RU2481823C2 (ru) * 2007-12-21 2013-05-20 Инспирейшн Биофармасьютикалс, Инк. Стабилизированные составы, содержащие фактор ix и трегалозу
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
PT2889043T (pt) * 2008-12-16 2019-07-16 Genzyme Corp Intermediários sintéticos para a preparação de conjugados oligossacárido-proteína
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP2663580B1 (en) 2011-01-10 2016-12-07 CT Atlantic Ltd. Combination therapy including tumor associated antigen binding antibodies
JP2014518889A (ja) 2011-06-03 2014-08-07 シーティー アトランティック リミテッド Ｍａｇｅａ３結合抗体
EP2714743A1 (en) 2011-06-03 2014-04-09 CT Atlantic Ltd. Magea3 binding antibodies
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
EP2802603A4 (en) 2012-01-09 2015-11-04 Scripps Research Inst REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
TWI750197B (zh) * 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
US10441531B2 (en) * 2012-11-09 2019-10-15 Bloodworks Protein stabilizing factors
AU2014225307A1 (en) 2013-03-08 2015-09-24 The Curators Of The University Of Missouri Methods and compositions for the treatment and/or prevention of type 1 diabetes
AU2014228938B2 (en) 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
CA2917814C (en) 2013-07-11 2022-12-13 The California Institute For Biomedical Research Coiled coil immunoglobulin fusion proteins and compositions thereof
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
KR102302634B1 (ko) 2013-09-13 2021-09-14 더 스크립스 리서치 인스티튜트 변형된 치료제 및 이의 조성물
CA2923705C (en) 2013-10-09 2024-05-14 Nestec S.A. Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome
AU2014337367B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
KR102357968B1 (ko) 2013-10-15 2022-02-03 더 스크립스 리서치 인스티튜트 키메라 항원 수용체 t 세포 스위치 및 이의 용도
JP6572497B2 (ja) 2013-12-18 2019-09-11 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、ステープル留めされたペプチド脂質複合体、及びそれらの組成物
EA202092926A3 (ru) 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
US11292838B2 (en) 2015-06-01 2022-04-05 Medigene Immunotherapies Gmbh Method for generating antibodies against T cell receptor
CN108026171A (zh) 2015-06-01 2018-05-11 基因医疗免疫疗法有限责任公司 T细胞受体特异性抗体
NZ737400A (en) 2015-06-01 2019-09-27 Medigene Immunotherapies Gmbh T cell receptor library
EP3310376A4 (en) 2015-06-17 2019-01-23 The California Institute for Biomedical Research MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
MX2017015817A (es) 2015-07-06 2018-04-10 Ucb Biopharma Sprl Anticuerpos de union a tau.
CA2996716A1 (en) 2015-09-04 2017-03-09 The California Institute For Biomedical Research Insulin immunoglobulin fusion proteins
EP3387019B1 (en) 2015-12-09 2021-10-20 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
CA3009564C (en) 2015-12-23 2023-08-29 Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Dendritic cell composition
AU2017345479B2 (en) 2016-10-19 2024-03-21 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
KR20220061977A (ko) 2019-08-12 2022-05-13 퓨리노미아 바이오테크, 아이엔씨. Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
EP4048405A2 (en) 2019-10-24 2022-08-31 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
AU2022264339A1 (en) 2021-04-28 2023-11-09 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
KR20240109277A (ko) 2021-12-01 2024-07-10 유씨비 바이오파마 에스알엘 Fab-peg를 포함하는 제제

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5480406A (en) * 1977-12-09 1979-06-27 Tanabe Seiyaku Co Ltd Preparation of urokinase for injection
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
US4495278A (en) 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4470968A (en) * 1983-01-13 1984-09-11 Miles Laboratories, Inc. Pasteurized therapeutically active blood coagulation factor concentrates
AT376881B (de) * 1983-05-02 1985-01-10 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4952675A (en) * 1985-02-01 1990-08-28 New York University Method for purifying antihemophilic factor
US4770999A (en) 1985-04-22 1988-09-13 Genetics Institute, Inc. High yield production of active Factor IX
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
DE3877529T2 (de) 1987-10-23 1996-11-07 Centre Regional De Transfusion Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung.
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
CA2078721A1 (en) * 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
JPH05331071A (ja) * 1992-01-17 1993-12-14 Asahi Chem Ind Co Ltd カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5733873A (en) * 1992-10-02 1998-03-31 Pharmacia & Upjohn Ab Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX

Also Published As

Publication number Publication date
PT758248E (pt) 2003-11-28
DE69531204D1 (de) 2003-08-07
JP4789698B2 (ja) 2011-10-12
ES2202356T3 (es) 2004-04-01
CA2182200A1 (en) 1995-11-02
EP0758248A1 (en) 1997-02-19
WO1995028954A1 (en) 1995-11-02
JPH09512267A (ja) 1997-12-09
ATE244015T1 (de) 2003-07-15
JP2006219500A (ja) 2006-08-24
EP0758248B1 (en) 2003-07-02
AU2207595A (en) 1995-11-16
JP2007224052A (ja) 2007-09-06
US6372716B1 (en) 2002-04-16
CA2182200C (en) 1999-02-02
AU695084B2 (en) 1998-08-06
JP2010077148A (ja) 2010-04-08
DE69531204T2 (de) 2004-04-22

Similar Documents

Publication Publication Date Title
DK0758248T3 (da) Formuleringer til faktor IX
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
ATE216590T1 (de) Arzneimittelformulierungen für il-12
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
WO2001005355A3 (en) Formulations for il-11
DK0548114T5 (da) Mometason-furoat-monohydrat, fremgangsmåde til fremtilling deraf og farmaceutiske præparater indeholdende dette
DK1149905T3 (da) Fremgangsmåder og præparat til polypeptidteknologi
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
DE69524742D1 (de) Interleukin-11 präparat
SE9201628D0 (sv) Pharmaceutical composition
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
ATE331037T1 (de) Isoliertes frpb nukleinsäuremolekül und entsprechende impfstoff
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
DE69102704D1 (de) Orales, melatonin enthaltendes arzneimittel.
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
DE69330601D1 (de) Serotoninergische ergolin derivate
ATE227122T1 (de) Stabilisierte tablettenformulierung
DK0656889T3 (da) 9-chlorprostaglandinestere og -amider og deres anvendelse ved fremstilling af lægemidler
UA42797C2 (uk) Похідні хінолон- і нафтиридонкарбонової кислоти та похідні ізоіндолу для їх одержання
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
BG104452A (en) New derivatives of the methylenebisphosphonic acid
DK0653932T3 (da) Midler til bruning af huden
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge